Bank of America Securities Raises PT on Metsera (MTSR), Keeps a Buy

Group 1 - Metsera, Inc. (NASDAQ:MTSR) is identified as one of the best stocks to buy for the next three months according to hedge funds, with Bank of America Securities raising the price target from $45 to $50 while maintaining a Buy rating [1][2] - The company reported significant progress in its obesity and metabolic disease drug pipeline, particularly with its lead drug MET-097i, which is a once-monthly GLP-1 receptor agonist showing strong potential for weight loss and good tolerability in Phase 2b trials [2][3] - Another drug, MET-233i, a once-monthly amylin analog, demonstrated impressive Phase 1 results with an 8.4% weight loss over five weeks and a 19-day half-life, with full 12-week monotherapy data expected by late 2025 [3] Group 2 - Metsera, Inc. is advancing oral peptide programs, with data from MET-097o and MET-224o anticipated in late 2025, indicating a robust pipeline of innovative injectable and oral hormone analog peptides [3]